Skip to the content
Know your tech before you buy it. Makers: get listed from $49/mo

CONVERGE

vergelabs.com

  • Web
6.1 Club score Visit vergelabs.com

What the maker publishes

Commercial access
Verge describes engagement models ranging from full target-discovery campaigns to focused human-relevance assessments. source
Company
Verge Labs says it started as Verge Genomics in 2015 and became Verge Labs in 2026. source
Data collection
VergeDB is built from brain tissue partnerships and includes transcriptomic, genetic, clinical, and multi-omics data. source
Founded
2015 source
Headquarters
San Francisco, California source
Model
Its model infers an individual patient's brain molecular state from a routine blood draw and predicts drug response. source
Product
CONVERGE is an AI operating system for neuroscience drug development combining foundation models and systems-biology workflows. source
Program enablement
CONVERGE helps teams evaluate target pathways, patient subgroups, preclinical models, and indication opportunities. source
Scale
The company's platform data page reports 12,000 brain transcriptomes, 6,000+ neurological patients and controls, and 15M single-cell profiles. source
Security and integrations
The opened official product pages do not state security certifications or third-party integrations. source
Support
Verge says it aims to reply to platform and partnership inquiries within two business days. source
Target discovery
The platform identifies disease signatures and targets using multimodal patient data and human tissue and genetics. source
Training data
The foundation model is trained on proprietary multimodal CNS patient data and can be tuned with program- and trial-specific data. source
Trial optimization
It stratifies trial populations by molecular endotype and identifies likely-benefit subgroups and pharmacodynamic biomarkers. source
Users
The product is presented for drug developers working on neuroscience and CNS programs. source

Checked against the maker's pages on 14 Nov 2026.